Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
albendazole + dexamethasone + levetiracetam
- Development stage
- Unknown
- Lead developer
- UCB
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of albendazole (an anthelmintic medication), dexamethasone (a corticosteroid), and levetiracetam (an antiepileptic drug). Levetiracetam works by binding to the synaptic vesicle protein SV2A in the brain, which helps reduce abnormal electrical activity. This combination may be used in specific clinical scenarios where parasitic infections affecting the central nervous system require management of both the infection (albendazole), inflammation (dexamethasone), and seizures (levetiracetam).
02
Targets
SV2A (Synaptic vesicle glycoprotein 2A)
Beyond the preview
Go deeper on albendazole + dexamethasone + levetiracetam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on albendazole + dexamethasone + levetiracetam.